Nautilus Biotechnology Inc (NAUT)
2.65
+0.08
(+3.11%)
USD |
NASDAQ |
Nov 05, 16:00
2.65
0.00 (0.00%)
After-Hours: 16:11
Nautilus Biotechnology Total Liabilities (Quarterly): 36.27M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 36.27M |
| June 30, 2024 | 37.47M |
| March 31, 2024 | 39.16M |
| December 31, 2023 | 40.21M |
| September 30, 2023 | 41.06M |
| June 30, 2023 | 41.09M |
| March 31, 2023 | 42.17M |
| December 31, 2022 | 35.13M |
| Date | Value |
|---|---|
| September 30, 2022 | 33.97M |
| June 30, 2022 | 34.15M |
| March 31, 2022 | 34.96M |
| December 31, 2021 | 34.87M |
| September 30, 2021 | 7.50M |
| June 30, 2021 | 3.231M |
| December 31, 2020 | 114.73M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
3.231M
Minimum
Jun 2021
114.73M
Maximum
Dec 2020
38.40M
Average
36.27M
Median
Sep 2024
Total Liabilities (Quarterly) Benchmarks
| Incyte Corp | 1.841B |
| Merck & Co Inc | 68.98B |
| Neogen Corp | 1.368B |
| Pfizer Inc | 128.22B |
| Repligen Corp | 875.56M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 259.70M |
| Shareholders Equity (Quarterly) | 223.43M |